Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma

Purpose

To assess the relationship between serum thyroglobulin (Tg) levels, Tg doubling time (Tg-DT) and the diagnostic performance of ¹⁸F-FDG PET/CT in detecting recurrences of ¹³¹I-negative differentiated thyroid carcinoma (DTC).

Methods

Included in the present study were 102 patients with DTC. All patients were treated by thyroid ablation (e.g. thyroidectomy and ¹³¹I), and underwent ¹⁸F-FDG PET/CT due to detectable Tg levels and negative conventional imaging. Consecutive serum Tg measurements performed before the ¹⁸F-FDG PET/CT examination were used for Tg-DT calculation. The ¹⁸F-FDG PET/CT results were assessed as true or false after histological and/or clinical follow-up.

Results

Serum Tg levels were higher in patients with a positive ¹⁸F-FDG PET/CT scan (median 6.7 ng/mL, range 0.7–73.6 ng/mL) than in patients with a negative scan (median 1.8 ng/mL, range 0.5–4.9 ng/mL; P?18F-FDG PET/CT scan, the Tg levels were >5.5 ng/mL, and in 31 (74 %) of 42 patients with a true-negative ¹⁸F-FDG PET/CT scan, the Tg levels were ≤5.5 ng/mL. A Tg-DT of <1 year was found in 46 of 49 patients (94 %) with a true-positive ¹⁸F-FDG PET/CT scan, and 40 of 42 patients (95 %) with a true-negative scan had a stable or increased Tg-DT. Moreover, combining Tg levels and Tg-DT as selection criteria correctly distinguished between patients with a positive and a negative scan (P<0.0001).

Conclusion

The accuracy of ¹⁸F-FDG PET/CT significantly improves when the serum Tg level is above 5.5 ng/mL during levothyroxine treatment or when the Tg-DT is less than 1 year, independent of the absolute value.